Related Experiment Video
Updated: Jun 13, 2025

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Ataluren-mediated nonsense variant readthrough in D-bifunctional protein deficiency: A case report
Rai-Hseng Hsu1,2,3, Ni-Chung Lee1,2,3, Hui-An Chen1,2,3
1Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
Insights
D-bifunctional protein deficiency, a severe peroxisomal disorder, was treated in an infant using the readthrough agent ataluren. This experimental therapy showed promise by improving clinical symptoms and reducing specific biomarker levels.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- D-bifunctional protein (DBP) deficiency is a fatal peroxisomal disorder impacting infants.
- Early diagnosis is crucial for managing life-threatening symptoms.
Observation:
- An infant diagnosed with DBP deficiency via HSD17B4 variant screening showed elevated C26:0-LPC levels.
- The infant presented with seizures, hypotonia, and developmental delays within the first year of life.
Findings:
- Treatment with PTC124 (ataluren) reduced C26:0-LPC levels from 0.65 μM to 0.53 μM.
- Fish oil supplementation caused a transient increase in C26:0-LPC.
- Over two years, the infant showed improved motor and speech development and no further seizures.
Implications:
- Nonsense readthrough therapy, like ataluren, offers a potential treatment for DBP deficiency.
- This approach may provide a targeted therapy for peroxisomal disorders lacking effective treatments.
Abstract:
D-bifunctional protein (DBP) deficiency, a fatal peroxisomal enzyme disorder, typically manifests with life-threatening symptoms in the first two years of childhood. We present the case of an infant with elevated lysophosphatidylcholine C26:0 (C26:0-LPC) levels identified during X-linked adrenoleukodystrophy (ALD) screening, leading to a diagnosis of DBP deficiency due to a homozygous HSD17B4 c.1041T>A, p.(Tyr347Ter) variant. Starting at two months of age, the infant experienced seizures, hypotonia, and developmental delays, prompting the initiation of experimental treatment with the readthrough agent PTC124 (ataluren) at six months. The treatment led to a decrease in C26:0-LPC levels from 0.65 μM to 0.53 μM; concomitant fish oil supplementation transiently increased C26:0-LPC to 0.74 μM before returning to 0.53 μM after cessation of supplementation. The patient demonstrated improved swallowing and progressive motor and speech development during a two-year treatment period, with no further seizures. This case report highlights the potential of nonsense readthrough therapy for peroxisomal disorders, a group of metabolic diseases that currently lack targeted treatments.
Related Concept Videos
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Translation
Translation Produces the Building Blocks of Life
Proteins are...
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Mutations
Leaky Scanning
RNA Splicing

